Compare ADPT & BSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADPT | BSM |
|---|---|---|
| Founded | 2009 | 1876 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Oil & Gas Production |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | 2019 | 2015 |
| Metric | ADPT | BSM |
|---|---|---|
| Price | $24.81 | $14.07 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 9 | 1 |
| Target Price | ★ $17.78 | $14.00 |
| AVG Volume (30 Days) | ★ 2.7M | 324.6K |
| Earning Date | 05-05-2026 | 05-04-2026 |
| Dividend Yield | N/A | ★ 8.40% |
| EPS Growth | ★ 63.89 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $276,976,000.00 | ★ $469,919,000.00 |
| Revenue This Year | $3.98 | $11.03 |
| Revenue Next Year | $22.72 | $9.63 |
| P/E Ratio | ★ N/A | $12.82 |
| Revenue Growth | ★ 54.77 | 8.35 |
| 52 Week Low | $11.93 | $11.90 |
| 52 Week High | $24.96 | $15.49 |
| Indicator | ADPT | BSM |
|---|---|---|
| Relative Strength Index (RSI) | 58.80 | 43.95 |
| Support Level | $15.08 | $13.46 |
| Resistance Level | N/A | $14.45 |
| Average True Range (ATR) | 1.38 | 0.29 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 66.50 | 16.36 |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.
Black Stone Minerals LP is an oil and natural gas mineral company. It owns oil and natural gas mineral interests, which makes up the majority of its asset base. Its business is actively managing an existing portfolio of mineral and royalty assets to maximize its value and expanding asset base through acquisitions of additional mineral and royalty interests. The company owns mineral interests in approximately 16.9 million gross acres.